NAV Stock Overview
NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NAVCO Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.03 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.02 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -14.29% |
| 1 Year Change | -68.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Shareholder Returns
| NAV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -14.3% | 3.4% | -0.2% |
| 1Y | -68.4% | -38.0% | 7.0% |
Return vs Industry: NAV underperformed the Canadian Biotechs industry which returned -39.6% over the past year.
Return vs Market: NAV underperformed the Canadian Market which returned 5.3% over the past year.
Price Volatility
| NAV volatility | |
|---|---|
| NAV Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: NAV's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NAV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Geoffrey Lee | navcopharma.com |
NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials. It offers aerosol spray, hand cream and sanitizer, and colloidal silver products. The company also provides COVID PCR testing, PPE, and diagnostic PCR testing, as well as textile and food solutions.
NAVCO Pharmaceuticals Inc. Fundamentals Summary
| NAV fundamental statistics | |
|---|---|
| Market cap | CA$2.00m |
| Earnings (TTM) | -CA$2.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs NAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.32m |
| Earnings | -CA$2.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -298.3% |
How did NAV perform over the long term?
See historical performance and comparison